Gilead quarterly revenue drops 4%, oral COVID drug fails trial
By Deena Beasley (Reuters) -Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment ...
Source: saltwire.com
Gilead Sciences On News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Gilead Sciences On. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Gilead Sciences On Today - Breaking & Trending Today
Gilead quarterly revenue drops 4%, oral COVID drug fails trial
Gilead Sciences on Tuesday said its fourth-quarter revenue dipped 4% on lower sales of HIV drugs and Veklury, an infused drug for hospitalized COVID-19 patients, while its adjusted profit rose 3% due...
Source: marketscreener.com
Gilead quarterly revenue drops 4%, oral COVID drug fails trial
Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment Veklury, and the company forecast weaker-than-expected 2024 sales. For full-year 2024, Gilead said it expects adjusted earnings of $6.85 to $7.25 per share on product sales of $27.1 billion to $27.5 billion. Analysts have projected 2024 earnings of $7.24 per share on revenue of $27.7 billion.
Source: yahoo.com
Advocates of the LGBT+ Community Honored at BET BLACK + Iconic Soiree
BET celebrated the intersectionality of the Black and LGBTQ+ community with annual BET BLACK + ICONIC SOIREE in Atlanta
Source: eurweb.com